/Doctor%20scientist%20looking%20at%20test%20tube%20solution%20by%20MIND%20AND%20I%20via%20Adobe%20Stock.jpeg)
Valued at a market cap of $127.1 billion, Stryker Corporation (SYK) is a global medical technology company that develops and sells a broad range of products designed to improve surgical procedures and patient outcomes. The Michigan-based company’s portfolio spans MedSurg and Neurotechnology, including surgical equipment, endoscopy systems, patient-handling solutions, emergency-care products, neurovascular devices, and neurosurgical technologies, as well as Orthopaedics, covering joint replacement implants, trauma and extremities products, and robotic-assisted surgical technologies such as Mako.
Stryker stock has been stuck in the recovery room while the broader market keeps running laps. SYK has declined 12.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 20.2%. The gap has persisted in 2026, with SYK slipping 3.3% YTD even as the broader index has climbed 12.6%.
Narrowing the focus, SYK has also trailed the iShares U.S. Medical Devices ETF (IHI), which has declined about 8.5% over the past year.
Stryker’s stock has been caught in a classic case of “good, but not good enough.” Investors have grown increasingly wary of slowing organic growth and softer sales momentum, concerns that came to a head after the company’s Q2 results release on July 30 sparked a 7.3% post-earnings selloff. Revenue climbed a respectable 9.4% to $6.59 billion, but merely met Wall Street’s expectations, while 9% organic sales growth fell short of forecasts. Even a 5.8% earnings beat, with adjusted EPS of $3.69, and a slight increase in full-year guidance couldn’t save the day, as investors zeroed in on the underwhelming top line as a potential warning sign of slowing demand.
Still, SYK got a much-needed boost on Aug. 19, when its shares jumped 2.7% after its Michigan-based Stryker Sales unit secured a $100 million contract modification from the U.S. Defense Logistics Agency, giving investors fresh confidence in the company’s government-related revenue pipeline.
For fiscal 2026, ending in December, analysts expect SYK’s EPS to grow 10.2% to $15.02 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the past four quarters, while missing on one occasion.
Among the 29 analysts covering SYK stock, the consensus is a “Strong Buy.” That’s based on 19 “Strong Buy” ratings, three “Moderate Buys,” and seven “Holds.”
This configuration is more bullish than two months ago, when the stock had 18 “Strong Buy” suggestions.
On Aug. 17, Citi raised its price target on Stryker to $399 from $385 while reiterating its “Buy” rating, reflecting a more constructive outlook on the medtech sector following Q2 earnings. The firm noted that companies remain confident about procedure volumes in the second half of 2026 and that 2027 earnings estimates now appear more reasonable, supporting its bullish stance on SYK.
The mean price target of $379.81 represents a 11.7% premium to SYK’s current price levels. The Street-high price target of $440 suggests an upside potential of 29.4%.
